Commodity	Region/NEU/SEU(a)	Residue levels observed in the supervised residue trials (mg/kg)	Comments/Source	Calculated MRL (mg/kg)	HR(b) (mg/kg)	STMR(c) (mg/kg)	CF(d)
Intended GAPs: Garlic, onions, shallots (2 × 0.10 kg a.s./ha, PHI 7 days)	NEU	Mo: Prothioconazole‐desthio: 6 × < 0.01; 2 × 0.012 Prothioconazole‐α‐hydroxy‐desthio: 8 × < 0.01 Prothioconazole‐3‐hydroxy‐desthio: 8 × < 0.01 Prothioconazole‐4‐hydroxy‐desthio: 8 × < 0.01 Prothioconazole‐5‐hydroxy‐desthio: 8 × < 0.01 Prothioconazole‐6‐hydroxy‐desthio: 8 × < 0.01	Residue trials on onions compliant with GAP. Extrapolation to garlic and shallots possible.	0.02	Mo: 0.012	Mo: 0.01	–
		Residue definition for risk assessment: Sum of prothioconazole‐desthio and all metabolites containing the 2‐(1‐chlorocyclopropyl)‐3‐(2‐chlorophenyl)‐2‐hydroxypropyl‐2H‐1,2,4‐ triazole moiety, expressed as prothioconazole‐desthio (sum of isomers)
		RA: 6 × < 0.06; 2 × 0.062		–	RA: 0.062	RA: 0.06	1
		Triazole‐derivate metabolites (TDMs)
		Residue definition for risk assessment: Triazole alanine (TA) and triazole lactic acid (TLA)
		Triazole alanine (TA): < 0.01; 0.012(e); 0.018; 0.034(f); 0.063(f); 0.074; 0.12(g); 0.14 Triazole lactic acid (TLA): 8 × < 0.01		– –	RATA: 0.14 RATLA: < 0.01	RATA: 0.05 RATLA: < 0.01
		Residue definition for risk assessment: Triazole acetic acid (TAA)
		Triazole acetic acid (TAA): 8 × < 0.01		–	RA TAA : < 0.01	RA TAA : < 0.01
		Residue definition for risk assessment: 1,2,4‐triazole (1,2,4‐T)
		1,2,4 – triazole (1,2,4‐T): 8 × < 0.01		–	RA 1,2,4‐T : < 0.01	RA 1,2,4‐T : < 0.01
	SEU	Mo: Prothioconazole‐desthio: 7 × < 0.01; 1 × 0.01 Prothioconazole‐α‐hydroxy‐desthio: 8 × < 0.01 Prothioconazole‐3‐hydroxy‐desthio: 8 × < 0.01 Prothioconazole‐4‐hydroxy‐desthio: 8 × < 0.01 Prothioconazole‐5‐hydroxy‐desthio: 8 × < 0.01 Prothioconazole‐6‐hydroxy‐desthio: 8 × < 0.01	Residue trials on onions compliant with GAP. Extrapolation to garlic and shallots possible.	0.02	Mo: 0.01	Mo: 0.01
		Residue definition for risk assessment: Sum of prothioconazole‐desthio and all metabolites containing the 2‐(1‐chlorocyclopropyl)‐3‐(2‐chlorophenyl)‐2‐hydroxypropyl‐2H‐1,2,4‐ triazole moiety, expressed as prothioconazole‐desthio (sum of isomers)
		RA: 7 × < 0.06; 1 × 0.06		–	RA: 0.06	RA: 0.06	1
		Triazole‐derivate metabolites (TDMs)
		Residue definition for risk assessment: Triazole alanine (TA) and triazole lactic acid (TLA)
		Triazole alanine (TA): < 0.01; 0.012(e); 0.013(e); 0.029(e); 0.039(g); 0.045(g); 0.048; 0.098(e); Triazole lactic acid (TLA): 8 × < 0.01		– –	RATA: 0.098 RATLA: < 0.01	RATA: 0.034 RATLA: < 0.01
		Residue definition for risk assessment: Triazole acetic acid (TAA)
		Triazole acetic acid (TAA): 8 × < 0.01		–	RATAA: < 0.01	RATAA: < 0.01
		Residue definition for risk assessment: 1,2,4‐triazole (1,2,4‐T)
		1,2,4 – triazole (1,2,4‐T): 8 × < 0.01		–	RA1,2,4‐T: < 0.01	RA1,2,4‐T: < 0.01

MRL: maximum residue level; GAP: Good Agricultural Practice; Mo: monitoring; RA: risk assessment. Individual conversion factors (CFs) between residues according to the RD for monitoring and the RD for risk assessment were not derived.

*: Indicates that the MRL is proposed at the limit of quantification.

(a) NEU: Outdoor trials conducted in northern Europe, SEU: Outdoor trials conducted in southern Europe.

(b) Highest residue. The highest residue for risk assessment refers to the whole commodity and not to the edible portion.

(c) Supervised trials median residue. The median residue for risk assessment refers to the whole commodity and not to the edible portion.

(d) Conversion factor between monitoring and risk assessment considering the median value of available trials.

(e) Higher residue value at a longer PHI of 14 days.

(f) Higher residue value in control sample.

(g) Higher value in control sample and at a longer PHI of 14 days.